Renin inhibition in the treatment of diabetic kidney disease

Clinical Science

Volumn 124, Issue 9, 2013, Pages 553-566

  Komers, Radko ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Aliskiren; Cyclo oxygenase 2; Diabetic nephropathy; Prorenin; Renin angiotensin system (RAS); Urocortin; Vitamin D

Indexed keywords

ALISKIREN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ENALAPRIL; G PROTEIN COUPLED RECEPTOR; IRBESARTAN; PARICALCITOL; PRORENIN RECEPTOR; RENIN INHIBITOR; ROFECOXIB; UROCORTIN; VALDECOXIB; VITAMIN D; VITAMIN D RECEPTOR;

ALBUMINURIA; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; HEART MUSCLE CELL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STREPTOZOCIN DIABETES;

AMIDES; ANIMALS; CYCLOOXYGENASE 2 INHIBITORS; DIABETIC NEPHROPATHIES; FUMARATES; HUMANS; KIDNEY FAILURE, CHRONIC; RECEPTORS, CALCITRIOL; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; RENIN; RENIN-ANGIOTENSIN SYSTEM; UROCORTINS; VITAMIN D;

EID: 84874698281     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20120468     Document Type: Review

References (144)

1. Weir, M. R. (2007) Renin inhibitors: novel agents for renoprotection or a better angiotensin receptor blocker for blood pressure lowering? Curr. Opin. Nephrol. Hypertens. 16, 416-421
2. Leibovitz, E. and Schiffrin, E. L. (2007) Novel drugs targeting hypertension: renin inhibitors and beyond. J. Cardiovasc. Pharmacol. 50, 3-8
3. Muller, D. N. and Luft, F. C. (2006) Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin. J. Am. Soc. Nephrol. 1, 221-228
4. Brosnihan, K. B., Li, P. and Ferrario, C. M. (1996) Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 27, 523-528
5. Tallant, E. A., Diz, D. I. and Ferrario, C. M. (1999) Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle. Hypertension 34, 950-957
6. Iyer, S. N., Ferrario, C. M. and Chappell, M. C. (1998) Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 31, 356-361
7. Zimmerman, D. and Burns, K. D. (2012) Angiotensin-(1-7) in kidney disease: a review of the controversies. Clin. Sci. 123, 333-346
8. Urata, H., Strobel, F and Ganten, D (1994) Widespread distribution of human chymase. J. Hypertens. 12, S17-S22
9. Wiemer, G., Scholkens, B., Becker, R. H. and Busse, R. (1991) Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 18, 558-563
10. Campbell, D. J., Kladis, A. and Duncan, A. M. (1994) Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 23, 439-449
11. Chappel, M. C., Pirro, M. T., Sykes, A. and Ferrario, C. M. (1998) Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension 31, 362-367
12. Azizi, M., Rousseau, A., Ezan, E., Guyene, T. T., Michelet, S., Grognet, J. M., Lenfant, M., Corvol, P. and Menard, J. (1996) Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J. Clin. Invest. 97, 839-844
13. Liao, T. D., Yang, X. P., D'Ambrosio, M., Zhang, Y., Rhaleb, N. E. and Carretero, O. A. (2010) N-Acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: council for high blood pressure research. Hypertension 55, 459-467
14. Siragy, H. M. and Carey, R. M. (1997) The subtype-2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J. Clin. Invest. 100, 264-269
15. Levy, B. I. (2004) Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 109, 8-13
16. Wolf, G., Ziyadeh, F. N., Thaiss, F., Tomaszewski, J., Caron, R J, Wenzel, U., Zahner, G., Helmchen, U. and Stahl, R. A. K. (1997) Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endotelial cell. Role of angiotensin type 2 receptor. J. Clin. Invest. 100, 1047-1058
17. Wolf, G., Wenzel, U., Burns, K. D., Harris, R. C., Stahl, R. A. and Thaiss, F. (2002) Angiotensin II activates nuclear transcription factor-κB through AT1 and AT2 receptors. Kidney Int. 61, 1986-1995
18. Staessen, J., Lijnen, P., Fagard, R., Verschueren, L. J. and Amery, A. (1981) Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J. Endocrinol. 91, 457-465
19. Bomback, A. S. and Klemmer, P. J. (2007) The incidence and implications of aldosterone breakthrough. Nat. Clin. Pract. Nephrol. 3, 486-492
20. Schjoedt, K. J., Andersen, S., Rossing, P., Tarnow, L. and Parving, H. H. (2004) Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 47, 1936-1939
21. Nussberger, J., Wuerzner, G., Jensen, C. and Brunner, H. R. (2002) Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 39, E1-8
22. Azizi, M., Menard, J., Bissery, A., Guyene, T. T. and Bura-Riviere, A. (2007) Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin. J. Am. Soc. Nephrol. 2, 947-955
23. Luft, F. C. and Weinberger, M. H. (2008) Antihypertensive therapy with aliskiren. Kidney Int. 73, 679-683
24. Gao, D., Ning, N., Niu, X., Wei, J., Sun, P. and Hao, G. (2011) Aliskiren vs. angiotensin receptor blockers in hypertension: meta-analysis of randomized controlled trials. Am. J. Hypertens. 24, 613-621
25. Zhenfeng, Z., Huilan, S., Junya, J., Dong, L. and Shan, L. (2011) A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension. JRAAS 12, 102-112
26. Ganten, D., Wagner, J., Zeh, K., Bader, M., Michel, J. B., Paul, M., Zimmermann, F., Ruf, P., Hilgenfeldt, U., Ganten, U. et al. (1992) Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc. Natl. Acad. Sci. U.S.A. 89, 7806-7810
27. Pilz, B., Shagdarsuren, E., Wellner, M., Fiebeler, A., Dechend, R., Gratze, P., Meiners, S., Feldman, D. L., Webb, R. L., Garrelds, I. M. et al. (2005) Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 46, 569-576
28. Feldman, D. L., Jin, L., Xuan, H., Contrepas, A., Zhou, Y., Webb, R. L., Mueller, D. N., Feldt, S., Cumin, F., Maniara, W. et al. (2008) Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 52, 130-136
29. Whaley-Connell, A., Nistala, R., Habibi, J., Hayden, M. R., Schneider, R. I., Johnson, M. S., Tilmon, R., Rehmer, N., Ferrario, C. M. and Sowers, J. R. (2010) Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. Am. J. Physiol. Renal Physiol. 298, F655-F661
30. Whaley-Connell, A., Habibi, J., Nistala, R., Hayden, M. R., Pulakat, L., Sinak, C., Locher, B., Ferrario, C. M. and Sowers, J. R. (2012) Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat. Regul. Pept. 176, 36-44
31. Gross, O., Girgert, R., Rubel, D., Temme, J., Theissen, S. and Muller, G. A. (2011) Renal protective effects of aliskiren beyond its antihypertensive property in a mouse model of progressive fibrosis. Am. J. Hypertens. 24, 355-361
32. Wu, W. P., Chang, C. H., Chiu, Y. T., Ku, C. L., Wen, M. C., Shu, K. H. and Wu, M. J. (2010) A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren. Am. J. Physiol. Renal Physiol. 299, F929-F941
33. Rusai, K., Schmaderer, C., Hermans, J. J., Lutz, J., Heemann, U. and Baumann, M. (2011) Direct renin inhibition in a rat model of chronic allograft injury. Transplantation 92, 999-1004
34. Durvasula, R. V. and Shankland, S. J. (2008) Activation of a local renin angiotensin system in podocytes by glucose. Am. J. Physiol. Renal Physiol. 294, F830-F839
35. Kelly, D. J., Zhang, Y., Moe, G., Naik, G. and Gilbert, R. E. (2007) Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 50, 2398-2404
36. Hartner, A., Cordasic, N., Klanke, B., Wittmann, M., Veelken, R. and Hilgers, K. F. (2007) Renal injury in streptozotocin-diabetic Ren2-transgenic rats is mainly dependent on hypertension, not on diabetes. Am. J. Physiol. Renal Physiol. 292, F820-F827
37. Persson, F., Rossing, P., Schjoedt, K. J., Juhl, T., Tarnow, L., Stehouwer, C. D., Schalkwijk, C., Boomsma, F., Frandsen, E. and Parving, H. H. (2008) Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int. 73, 1419-1425
38. Persson, F., Rossing, P., Reinhard, H., Juhl, T., Stehouwer, C. D., Schalkwijk, C., Danser, A. J., Boomsma, F., Frandsen, E. and Parving, H. H. (2009) Renal effects of aliskiren compared to and in combination with irbesartan in patients with type 2 diabetes, hypertension and albuminuria. Diabetes Care 32, 1873-1879
39. Parving, H. H., Persson, F., Lewis, J. B., Lewis, E. J. and Hollenberg, N. K. (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433-2446
40. Rossing, K. and Parving, H. H. (2005) Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy. Diabetes Care 28, 2106-2112
41. Persson, F., Lewis, J. B., Lewis, E. J., Rossing, P., Hollenberg, N. K. and Parving, H. H. (2010) Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care 33, 2304-2309
42. Persson, F., Lewis, J. B., Lewis, E. J., Rossing, P., Hollenberg, N. K. and Parving, H. H. (2011) Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. Clin. J. Am. Soc. Nephrol. 6, 1025-1031
43. Delea, T. E., Sofrygin, O., Palmer, J. L., Lau, H., Munk, V. C., Sung, J., Charney, A., Parving, H. H. and Sullivan, S. D. (2009) Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. J. Am. Soc. Nephrol. 20, 2205-2213
44. Parving, H. H., Brenner, B. M., McMurray, J. J., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Ghadanfar, M., Weissbach, N., Xiang, Z. et al. (2009) Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol. Dial. Transplant. 24, 1663-1671
45. Solomon, S. D., Shin, S. H., Shah, A., Skali, H., Desai, A., Kober, L., Maggioni, A. P., Rouleau, J. L., Kelly, R. Y., Hester, A. et al. (2011) Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur. Heart J. 32, 1227-1234
46. Harel, Z., Gilbert, C., Wald, R., Bell, C., Perl, J., Juurlink, D., Beyene, J. and Shah, P. S. (2012) The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ 344, e42
47. Nguyen, G. and Danser, A. H. (2008) Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents. Exp. Physiol. 93, 557-563
48. Batenburg, W. W. and Danser, A. H. (2012) (Pro)renin and its receptors: pathophysiological implications. Clin. Sci. 123, 121-133
49. Nguyen, G., Delarue, F., Burckle, C., Bouzhir, L., Giller, T. and Sraer, J. D. (2002) Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 109, 1417-1427
50. Feldt, S., Maschke, U., Dechend, R., Luft, F. C. and Muller, D. N. (2008) The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling. J. Am. Soc. Nephrol. 19, 743-748
51. Jackson, C. E., MacDonald, M. R., Petrie, M. C., Solomon, S. D., Pitt, B., Latini, R., Maggioni, A. P., Smith, B. A., Prescott, M. F., Lewsey, J. and McMurray, J. J. (2011) Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. Eur. J. Heart Failure 13, 746-754
52. Luetscher, J. A., Kraemer, F. B., Wilson, D. M., Schwartz, H. C. and Bryer-Ash, M. (1985) Increased plasma inactive renin in diabetes mellitus: a marker of microvascular complications. N. Engl. J. Med. 312, 1412-1417
53. Deinum, J., Ronn, B., Mathiesen, E., Derkx, F. H., Hop, W. C. and Schalekamp, M. A. (1999) Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia 42, 1006-1010
54. Suzuki, F., Hayakawa, M., Nakagawa, T., Nasir, U. M., Ebihara, A., Iwasawa, A., Ishida, Y., Nakamura, Y. and Murakami, K. (2003) Human prorenin has 'gate and handle' regions for its non-proteolytic activation. J. Biol. Chem. 278, 22217-22222
55. Ichihara, A., Hayashi, M., Kaneshiro, Y., Suzuki, F., Nakagawa, T., Tada, Y., Koura, Y., Nishiyama, A., Okada, H., Uddin, M. N. et al. (2004) Inhibition of diabetic nephropathy by a decoy peptide corresponding to the 'handle' region for nonproteolytic activation of prorenin. J. Clin. Invest. 114, 1128-1135
56. Ichihara, A., Suzuki, F., Nakagawa, T., Kaneshiro, Y., Takemitsu, T., Sakoda, M., Nabi, A. H., Nishiyama, A., Sugaya, T., Hayashi, M. and Inagami, T. (2006) Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J. Am. Soc. Nephrol. 17, 1950-1961
57. Takahashi, H., Ichihara, A., Kaneshiro, Y., Inomata, K., Sakoda, M., Takemitsu, T., Nishiyama, A. and Itoh, H. (2007) Regression of nephropathy developed in diabetes by (pro)renin receptor blockade. J. Am. Soc. Nephrol. 18, 2054-2061
58. Ichihara, A., Sakoda, M., Kurauchi-Mito, A., Nishiyama, A. and Itoh, H. (2008) Involvement of receptor-bound prorenin in development of nephropathy in diabetic db/db mice. J. Am. Soc. Hypertens. 2, 332-340
59. He, M., Zhang, L., Shao, Y., Wang, X., Huang, Y., Yao, T. and Lu, L. (2009) Inhibition of renin/prorenin receptor attenuated mesangial cell proliferation and reduced associated fibrotic factor release. Eur. J. Pharmacol. 606, 155-161
60. Huang, J., Matavelli, L. C. and Siragy, H. M. (2010) Renal (pro)renin receptor contributes to development of diabetic kidney disease through transforming growth factor-β1-connective tissue growth factor signalling cascade. Clin. Exp. Pharmacol. Physiol. 38, 215-221
61. Satofuka, S., Ichihara, A., Nagai, N., Noda, K., Ozawa, Y., Fukamizu, A., Tsubota, K., Itoh, H., Oike, Y. and Ishida, S. (2009) (Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes 58, 1625-1633
62. Veniant, M., Menard, J., Bruneval, P., Morley, S., Gonzales, M. F. and Mullins, J. (1996) Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J. Clin. Invest. 98, 1966-1970
63. Burckle, C. and Bader, M. (2006) Prorenin and its ancient receptor. Hypertension 48, 549-551
64. Kaneshiro, Y., Ichihara, A., Sakoda, M., Takemitsu, T., Nabi, A. H., Uddin, M. N., Nakagawa, T., Nishiyama, A., Suzuki, F., Inagami, T. and Itoh, H. (2007) Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats. J. Am. Soc. Nephrol. 18, 1789-1795
65. Ichihara, A., Kaneshiro, Y., Takemitsu, T., Sakoda, M., Suzuki, F., Nakagawa, T., Nishiyama, A., Inagami, T. and Hayashi, M. (2006) Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 47, 894-900
66. Ryuzaki, M., Ichihara, A., Ohshima, Y., Sakoda, M., Kurauchi-Mito, A., Narita, T., Kinouchi, K., Murohashi-Bokuda, K., Nishiyama, A. and Itoh, H. (2011) Involvement of activated prorenin in the pathogenesis of slowly progressive nephropathy in the non-clipped kidney of two kidney, one-clip hypertension. Hypertens. Res. 34, 301-307
67. Batenburg, W. W., Krop, M., Garrelds, I. M., de Vries, R., de Bruin, R. J., Burckle, C. A., Muller, D. N., Bader, M., Nguyen, G. and Danser, A. H. (2007) Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J. Hypertens. 25, 2441-2453
68. Feldt, S., Batenburg, W. W., Mazak, I., Maschke, U., Wellner, M., Kvakan, H., Dechend, R., Fiebeler, A., Burckle, C., Contrepas, A. et al. (2008) Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 51, 682-688
69. Muller, D. N., Klanke, B., Feldt, S., Cordasic, N., Hartner, A., Schmieder, R. E., Luft, F. C. and Hilgers, K. F. (2008) (Pro)renin receptor peptide inhibitor 'handle-region' peptide does not affect hypertensive nephrosclerosis in Goldblatt rats. Hypertension 51, 676-681
70. Krebs, C., Weber, M., Steinmetz, O., Meyer-Schwesinger, C., Stahl, R., Danser, A. H., Garrelds, I., van Goor, H., Nguyen, G., Muller, D. and Wenzel, U. (2008) Effect of (pro)renin receptor inhibition by a decoy peptide on renal damage in the clipped kidney of Goldblatt rats. Kidney Int. 74, 823-824
71. Peters, B., Grisk, O., Becher, B., Wanka, H., Kuttler, B., Ludemann, J., Lorenz, G., Rettig, R., Mullins, J. J. and Peters, J. (2008) Dose-dependent titration of prorenin and blood pressure in Cyp1a1ren-2 transgenic rats: absence of prorenin-induced glomerulosclerosis. J. Hypertens. 26, 102-109
72. Mercure, C., Prescott, G., Lacombe, M. J., Silversides, D. W. and Reudelhuber, T. L. (2009) Chronic increases in circulating prorenin are not associated with renal or cardiac pathologies. Hypertension 53, 1062-1069
73. Advani, A., Kelly, D. J., Cox, A. J., White, K. E., Advani, S. L., Thai, K., Connelly, K. A., Yuen, D., Trogadis, J., Herzenberg, A. M. et al. (2009) The (pro)renin receptor: site-specific and functional linkage to the vacuolar H+-ATPase in the kidney. Hypertension 54, 261-269
74. Kinouchi, K., Ichihara, A., Sano, M., Sun-Wada, G. H., Wada, Y., Kurauchi-Mito, A., Bokuda, K., Narita, T., Oshima, Y., Sakoda, M. et al. (2010) The (pro)renin receptor/ATP6AP2 is essential for vacuolar H+-ATPase assembly in murine cardiomyocytes. Circ. Res. 107, 30-34
75. Cruciat, C. M., Ohkawara, B., Acebron, S. P., Karaulanov, E., Reinhard, C., Ingelfinger, D., Boutros, M. and Niehrs, C. (2010) Requirement of prorenin receptor and vacuolar H+ -ATPasemediated acidification for Wnt signaling. Science 327, 459-463
76. Oshima, Y., Kinouchi, K., Ichihara, A., Sakoda, M., Kurauchi-Mito, A., Bokuda, K., Narita, T., Kurosawa, H., Sun-Wada, G. H., Wada, Y. et al. (2011) Prorenin receptor is essential for normal podocyte structure and function. J. Am. Soc. Nephrol. 22, 2203-2212
77. Riediger, F., Quack, I., Qadri, F., Hartleben, B., Park, J. K., Potthoff, S. A., Sohn, D., Sihn, G., Rousselle, A., Fokuhl, V. et al. (2011) Prorenin receptor is essential for podocyte autophagy and survival. J. Am. Soc. Nephrol. 22, 2193-2202
78. Zhang, J., Gu, C., Noble, N. A., Border, W. A. and Huang, Y. (2011) Combining angiotensin II blockade and renin receptor inhibition results in enhanced antifibrotic effect in experimental nephritis. Am. J. Physiol. Renal Physiol. 301, F723-F732
79. Cheng, H., Fan, X., Moeckel, G. W. and Harris, R. C. (2011) Podocyte COX-2 exacerbates diabetic nephropathy by increasing podocyte (pro)renin receptor expression. J. Am. Soc. Nephrol. 22, 1240-1251
80. Zhang, Z., Zhang, Y., Ning, G., Deb, D. K., Kong, J. and Li, Y. C. (2008) Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc. Natl. Acad. Sci. U.S.A. 105, 15896-15901
81. Deb, D. K., Sun, T., Wong, K. E., Zhang, Z., Ning, G., Zhang, Y., Kong, J., Shi, H., Chang, A. and Li, Y. C. (2010) Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int. 77, 1000-1009
82. Kuhlmann, A., Haas, C. S., Gross, M. L., Reulbach, U., Holzinger, M., Schwarz, U., Ritz, E. and Amann, K. (2004) 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am. J. Physiol. Renal Physiol. 286, F526-F533
83. Schwarz, U., Amann, K., Orth, S. R., Simonaviciene, A., Wessels, S. and Ritz, E. (1998) Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int. 53, 1696-1705
84. Hirata, M., Makibayashi, K., Katsumata, K., Kusano, K., Watanabe, T., Fukushima, N. and Doi, T. (2002) 22-Oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats. Nephrol. Dial. Transplant. 17, 2132-2137
85. Makibayashi, K., Tatematsu, M., Hirata, M., Fukushima, N., Kusano, K., Ohashi, S., Abe, H., Kuze, K., Fukatsu, A., Kita, T. and Doi, T. (2001) A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am. J. Pathol. 158, 1733-1741
86. Tan, X., Li, Y. and Liu, Y. (2006) Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J. Am. Soc. Nephrol. 17, 3382-3393
87. Agarwal, R., Acharya, M., Tian, J., Hippensteel, R. L., Melnick, J. Z., Qiu, P., Williams, L. and Batlle, D. (2005) Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 68, 2823-2828
88. Alborzi, P., Patel, N. A., Peterson, C., Bills, J. E., Bekele, D. M., Bunaye, Z., Light, R. P. and Agarwal, R. (2008) Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 52, 249-255
89. Szeto, C. C., Chow, K. M., Kwan, B. C., Chung, K. Y., Leung, C. B. and Li, P. K. (2008) Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial. Am. J. Kidney Dis. 51, 724-731
90. Kim, M. J., Frankel, A. H., Donaldson, M., Darch, S. J., Pusey, C. D., Hill, P. D., Mayr, M. and Tam, F. W. (2011) Oral cholecalciferol decreases albuminuria and urinary TGF-ß1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Kidney Int. 80, 851-860
91. de Zeeuw, D., Agarwal, R., Amdahl, M., Audhya, P., Coyne, D., Garimella, T., Parving, H. H., Pritchett, Y., Remuzzi, G., Ritz, E. and Andress, D. (2010) Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376, 1543-1551
92. Resnick, L. M., Muller, F. B. and Laragh, J. H. (1986) Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann. Intern. Med. 105, 649-654
93. Burgess, E. D., Hawkins, R. G. and Watanabe, M. (1990) Interaction of 1,25-dihydroxyvitamin D and plasma renin activity in high renin essential hypertension. Am. J. Hypertens. 3, 903-905
94. Forman, J. P., Williams, J. S. and Fisher, N. D. (2010) Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension 55, 1283-1288
95. Tomaschitz, A., Pilz, S., Ritz, E., Grammer, T., Drechsler, C., Boehm, B. O. and Marz, W. (2010) Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin. Chim. Acta 411, 1354-1360
96. Li, Y. C., Kong, J., Wei, M., Chen, Z. F., Liu, S. Q. and Cao, L. P. (2002) 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 110, 229-238
97. Yuan, W., Pan, W., Kong, J., Zheng, W., Szeto, F. L., Wong, K. E., Cohen, R., Klopot, A., Zhang, Z. and Li, Y. C. (2007) 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J. Biol. Chem. 282, 29821-29830
98. Kong, J., Qiao, G., Zhang, Z., Liu, S. Q. and Li, Y. C. (2008) Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. Kidney Int. 74, 1577-1581
99. Zhou, C., Lu, F., Cao, K., Xu, D., Goltzman, D. and Miao, D. (2008) Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1a-hydroxylase knockout mice. Kidney Int. 74, 170-179
100. Deb, D. K., Chen, Y., Zhang, Z., Zhang, Y., Szeto, F. L., Wong, K. E., Kong, J. and Li, Y. C. (2009) 1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-κB pathway. Am. J. Physiol. Renal Physiol. 296, F1212-F1218
101. Bodyak, N., Ayus, J. C., Achinger, S., Shivalingappa, V., Ke, Q., Chen, Y. S., Rigor, D. L., Stillman, I., Tamez, H., Kroeger, P. E. et al. (2007) Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc. Natl. Acad. Sci. U.S.A. 104, 16810-16815
102. Freundlich, M., Quiroz, Y., Zhang, Z., Zhang, Y., Bravo, Y., Weisinger, J. R., Li, Y. C. and Rodriguez-Iturbe, B. (2008) Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int. 74, 1394-1402
103. Park, C. W., Oh, Y. S., Shin, Y. S., Kim, C. M., Kim, Y. S., Kim, S. Y., Choi, E. J., Chang, Y. S. and Bang, B. K. (1999) Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am. J. Kidney Dis. 33, 73-81
104. Sugden, J. A., Davies, J. I., Witham, M. D., Morris, A. D. and Struthers, A. D. (2008) Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabetic Med. 25, 320-325
105. Wang, Y., Borchert, M. L. and Deluca, H. F. (2012) Identification of the vitamin D receptor in various cells of the mouse kidney. Kidney Int. 81, 993-1001
106. Wiley, K. E. and Davenport, A. P. (2004) CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. Br. J. Pharmacol. 143, 508-514
107. Bale, T. L., Hoshijima, M., Gu, Y., Dalton, N., Anderson, K. R., Lee, K. F., Rivier, J., Chien, K. R., Vale, W. W. and Peterson, K. L. (2004) The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc. Natl. Acad. Sci. U.S.A. 101, 3697-3702
108. Rademaker, M. T., Charles, C. J., Espiner, E. A., Frampton, C. M., Lainchbury, J. G. and Richards, A. M. (2005) Endogenous urocortins reduce vascular tone and renin-aldosterone/ endothelin activity in experimental heart failure. Eur. Heart J. 26, 2046-2054
109. Rademaker, M. T., Cameron, V. A., Charles, C. J. and Richards, A. M. (2005) Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation 112, 3624-3632
110. Davis, M. E., Pemberton, C. J., Yandle, T. G., Fisher, S. F., Lainchbury, J. G., Frampton, C. M., Rademaker, M. T. and Richards, M. (2007) Urocortin 2 infusion in human heart failure. Eur. Heart J. 28, 2589-2597
111. Rademaker, M. T., Charles, C. J., Nicholls, M. G. and Richards, A. M. (2008) Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure. Clin. Sci. 114, 635-642
112. Yang, C., Liu, X. and Li, S. (2010) Effect of long-term treatment with urocortin on the activity of somatic angiotensin-converting enzyme in spontaneously hypertensive rats. Can. J. Physiol. Pharmacol. 88, 168-176
113. Rademaker, M. T., Charles, C. J., Ellmers, L. J., Lewis, L. K., Nicholls, M. G. and Richards, A. M. (2011) Prolonged urocortin administration in experimental heart failure: sustained hemodynamic, endocrine, and renal effects. Hypertension 57, 1136-1144
114. Li, X., Hu, J., Zhang, R., Sun, X., Zhang, Q., Guan, X., Chen, J., Zhu, Q. and Li, S. (2008) Urocortin ameliorates diabetic nephropathy in obese db/db mice. Br. J. Pharmacol. 154, 1025-1034
115. Li, X., Hu, J., Zhang, Q., Sun, X. and Li, S. (2009) Urocortin 1 improves renal function in rats with streptozotocin-induced diabetes by inhibiting overproduction of TGF-ß1 and VEGF. Br. J. Pharmacol. 157, 994-1003
116. Chen, A., Brar, B., Choi, C. S., Rousso, D., Vaughan, J., Kuperman, Y., Kim, S. N., Donaldson, C., Smith, S. M., Jamieson, P. et al. (2006) Urocortin 2 modulates glucose utilization and insulin sensitivity in skeletal muscle. Proc. Natl. Acad. Sci. U.S.A. 103, 16580-16585
117. He, W., Miao, F. J., Lin, D. C., Schwandner, R. T., Wang, Z., Gao, J., Chen, J. L., Tian, H. and Ling, L. (2004) Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature 429, 188-193
118. Toma, I., Kang, J. J., Sipos, A., Vargas, S., Bansal, E., Hanner, F., Meer, E. and Peti-Peterdi, J. (2008) Succinate receptor GPR91 provides a direct link between high glucose levels and renin release in murine and rabbit kidney. J. Clin. Invest. 118, 2526-2534
119. Vargas, S. L., Toma, I., Kang, J. J., Meer, E. J. and Peti-Peterdi, J. (2009) Activation of the succinate receptor GPR91 in macula densa cells causes renin release. J. Am. Soc. Nephrol. 20, 1002-1011
120. Komers, R., Lindsley, J. N., Oyama, T. T., Schutzer, W. E., Reed, J. F., Mader, S. L. and Anderson, S. (2001) Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J. Clin. Invest. 107, 889-898
121. Komers, R., Lindsley, J. N., Oyama, T. T., Allison, K. M. and Anderson, S. (2000) Role of neuronal NOS (NOS1) in the pathogenesis of renal hemodynamic changes in diabetes. Am. J. Physiol. Renal Physiol. 279, F573-F583
122. Sapieha, P., Sirinyan, M., Hamel, D., Zaniolo, K., Joyal, J. S., Cho, J. H., Honore, J. C., Kermorvant-Duchemin, E., Varma, D. R., Tremblay, S. et al. (2008) The succinate receptor GPR91 in neurons has a major role in retinal angiogenesis. Nat. Med. 14, 1067-1076
123. Bhuniya, D., Umrani, D., Dave, B., Salunke, D., Kukreja, G., Gundu, J., Naykodi, M., Shaikh, N. S., Shitole, P., Kurhade, S. et al. (2011) Discovery of a potent and selective small molecule hGPR91 antagonist. Bioorg. Med. Chem. Lett. 21, 3596-3602
124. Harris, R. C., McKanna, J. A., Akai, Y., Jacobson, H. R., Dubois, R. N. and Breyer, M. D. (1994) Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J. Clin. Invest. 94, 2504-2510
125. Ichihara, A., Imig, J. D. and Navar, L. G. (1999) Cyclooxygenase-2 modulates afferent arteriolar responses to increases in pressure. Hypertension 34, 843-847
126. Harding, P., Sigmon, D. H., Alfie, M. E., Huang, P. L., Fishman, M. C., Beierwaltes, W. H. and Carretero, O. A. (1997) Cyclooxygenase-2 mediates increased renal renin content by low-sodium diet. Hypertension 29, 297-302
127. Traynor, T. R., Smart, A., Briggs, J. P. and Schnermann, J. (1999) Inhibition of macula densa-stimulated renin secretion by pharmacological blockade of cyclooxygenase-2. Am. J. Physiol. 277, F706-F710
128. Yang, T., Endo, Y., Huang, Y., Smart, A., Briggs, J. P. and Schnermann, J. B. (2000) Renin expression in COX-2-knockout mice on normal or low-salt diets. Am. J. Physiol. Renal Physiol. 279, F819-F825
129. Cheng, H.-F., Wang, J.-L., Zhang, M.-Z., Miyazaki, Y., Ichikawa, I., McKanna, J. A. and Harris, R. C. (1999) Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J. Clin. Invest. 103, 953-961
130. Cheng, H.-F., Wang, J.-L., Zhang, M.-Z., Wang, S.-W., McKanna, J. A. and Harris, R. C. (2001) Genetic deletion of COX-2 prevents increased renin expression in response to ACE inhibition. Am. J. Physiol. Renal Physiol. 280, F449-F456
131. Hartner, A., Goppelt-Straube, M. and Hilgers, K. F. (1998) Coordinate expression of cyclooxygenase-2 and renin in the rat kidney in renovascular hypertension. Hypertension 31, 201-205
132. Wang, J.-L., Cheng, H.-F. and Harris, R. C. (1999) Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension 34, 96-101
133. Kömhoff, M., Jeck, N. D. M., Seyberth, H. W., Gröne, H., Nüsing, R. M. and Breyer, D. (2001) Cyclooxygenase-2 expression is associated with the renal macula densa of patients with Bartter-like syndrome. Kidney Int. 58, 2420-2424
134. Komers, R., Lindsley, J. N., Oyama, T. T. and Anderson, S. (2007) Cyclo-oxygenase-2 inhibition attenuates the progression of nephropathy in uninephrectomized diabetic rats. Clin. Exp. Pharmacol. Physiol. 34, 36-41
135. Wang, J.-L., Cheng, H.-F., Shappell, S. and Harris, R. C. (2000) A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int. 57, 2334-2342
136. Komers, R., Tian, W., Lindsley, J. N., Oyama, T. T., Cohen, D. M. and Anderson, S. (2002) Effects of cyclooxygenase-2 (COX-2) inhibition on plasma and renal renin in diabetes. J. Lab. Clin. Med. 140, 351-357
137. Rossat, J., Maillard, M., Nussberger, J., Brunner, H. R. and Burnier, M. (1999) Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin. Pharmacol. Ther. 66, 76-84
138. Rodriguez, F., Llinas, M. T., Gonzales, J. D., Rivera, J. and Salazar, F. J. (2000) Renal changes induced by a cyclooxygenase-2 inhibitor during normal and low sodium intake. Hypertension 36, 276-281
139. Kammerl, M. C., Nusing, R. M., Seyberth, H. W., Riegger, G. A., Kurtz, A. and Kramer, B. K. (2001) Inhibition of cyclooxygenase- attenuates urinary prostanoid excretion without affecting renal renin expression. Pflugers Arch. 442, 842-847
140. Mann, B., Hartner, A., Jensen, B. L., Hilgers, K. F., Hocherl, K., Kramer, B. K. and Kurtz, A. (2001) Acute upregulation of COX-2 by renal artery stenosis. Am. J. Physiol. Renal Physiol. 280, F119-F125
141. Mangat, H., Peterson, L. N. and Burns, K. D. (1997) Hypercalcemia stimulates expression of intrarenal phospholipase A2 and prostaglandin H synthase-2 in rats. J. Clin. Invest. 100, 1941-1950
142. Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A. et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092-1102
143. McGettigan, P. and Henry, D. (2011) Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 8, e1001098
144. White, W. B., Faich, G., Borer, J. S. and Makuch, R. W. (2003) Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-inhibitor celecoxib. Am. J. Cardiol. 92, 411-418